Directly managed by our cross-functional teams to eliminate tech-transfer failure points across drug candidates, botanical actives, and specialized dosage configurations.
The late-stage pharmaceutical and high-tier botanical drug space demands a structural shift from simple toll extraction to complex Original Design Manufacturing (ODM) backed by multi-omic characterization.
Navigating FDA Botanical Drug Guidance or NMPA Class 1/6 natural medicine pathways requires multi-constituent chromatographic alignment. Modern Phase III contract manufacturers must guarantee reproducible phytochemical metabolomic ratios across commercial tonnages.
Moving beyond batch stirring tanks, Phase III industrialization is adopting continuous multi-stage supercritical extraction, resin membrane partitioning, and online process analytical technology (PAT) to strictly cap solvent residuals and thermal degradation.
Late-stage clinical batches require complete traceability from raw wildcrafted or cultivated herb origin through HPLC/HPTLC assay profiles to finished oral solid doses, ensuring compliance with 21 CFR Part 11 and international validation benchmarks.
Global biopharma sourcing managers navigating Phase III investigational materials confront four fundamental operational risks. Here is how specialized ODM engineering mitigates each vulnerability.
Botanical actives fluctuate across climate zones, harvest cut-offs, and ecological niches. Through geo-climatic potency modeling across different origins and harvest seasons, we identify optimum harvesting windows and lock down chemotypic stability prior to mass commercial extraction.
Phase III manufacturing represents the critical interface before intellectual property enters open-market production. Operating strictly on an entrusted contract research and manufacturing framework, clients maintain uncompromised exclusive ownership of master batch production records, patents, and chromatography libraries.
Strict pesticide limits, heavy metals, aflatoxins, and genotoxic residual solvents represent the top cause of import rejections. MedGence’s pilot and CDMO sites run ultra-trace ICP-MS and GC-MS/MS testing protocols exceeding USP <561> and EP European Pharmacopoeia safety specifications.
Harmonizing laboratory screening, toxicology profiling, and large-scale industrialization under a unified technical governance umbrella.
Having completed modern scientific characterizations of 83 classic Traditional Chinese Medicine formulas and 22 innovative natural compounds, our team translates empiric historical efficacy into verifiable mechanism of action (MoA) packages for NDA and global botanical registrations.
Bridge early discovery directly to Phase III trials with in vitro phenotypic assays, acute toxicity (LD50), chronic repeat-dose, and mammalian genotoxicity evaluations designed to pass FDA Investigational New Drug (IND) and registrational scrutiny.
We provide end-to-end execution of Phase I to Phase IV human clinical trials, covering patient enrollment strategies across accredited hospitals, GCP-compliant monitoring, randomized double-blind placebo packaging, and full statistical analysis reporting (SAR).
As articulated by our Scientific Leadership Team:
“Natural medicine earns global trust only when every claim is backed by reproducible chemistry, validated methods and controlled studies. We combine classical TCM formulation experience with modern analytical and pharmacological tools, so each ingredient we deliver can be traced, quantified and defended in front of regulators and consumers.”
— MedGence Technical Leadership, supporting over 100 enterprise partners including Tongrentang, CR Sanjiu, Livzon, Humanwell, and affiliated university hospitals.
Strategic blueprint detailing the convergence of computational chemistry, synthetic biology, and predictive pharmacology in late-stage manufacturing.
Integrating machine learning molecular docking models against human disease pathways to pinpoint active botanical synergists within multi-herb compounds, accelerating phase translation by up to 40%.
Scaling engineered yeast and micro-algae fermentation systems for rare triterpenoids and ginsenosides that are otherwise unsustainable or cost-prohibitive via traditional wild harvesting.
Formulating poorly soluble flavonoids and polyphenols into target-specific nano-encapsulations, oral liquids, sustained-release micro-beads, and advanced softgels for enhanced pharmacokinetic absorption.
Detailed technical and commercial answers addressing regulatory readiness, quality governance, and clinical transfer protocols.
Select a specialized manufacturing or analytical module below to request comprehensive master specifications and clinical development briefs.
